David A. Siegel Pro Qr Therapeutics N.V. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 61,000 shares of PRQR stock, worth $108,580. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,000
Previous 29,200
108.9%
Holding current value
$108,580
Previous $79,000
2.53%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PRQR
# of Institutions
69Shares Held
42.1MCall Options Held
30.1KPut Options Held
5.3K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.1MShares$14.4 Million0.02% of portfolio
-
Privium Fund Management B.V.4.99MShares$8.87 Million1.74% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.28MShares$5.85 Million0.49% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.07MShares$3.69 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY2.05MShares$3.66 Million1.03% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $127M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...